Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Ecnoglutide

Investigational

GLP-1 receptor agonist

Also known as: XW003, GLXC-26838, XW-003, DA-63110

Evidence score

63/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 15 registered studies on ClinicalTrials.gov, most advanced Phase 3
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Ecnoglutide, also known as XW003, is an investigational long-acting synthetic peptide that activates the GLP-1 receptor. Like other drugs in this class, it is thought to act on insulin release, appetite, and stomach emptying. It is designed with a signaling bias intended to favor certain receptor pathways.

What the evidence shows

Automatic summaryLimited human data

Ecnoglutide is not FDA-approved. It has 15 registered human trials reaching Phase 3 and about 16 published papers, with studies in type 2 diabetes and weight management, but its benefits and safety are not yet established by regulatory review.

Key facts

Molecular formula

C194H304N48O61

Molecular weight

4285 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

15registered studies

Phase 3most advanced phase

7completed (sample)

5recruiting (sample)

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Phase 2CompletedNCT07281937

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Phase 1CompletedNCT05184322

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

Phase 1RecruitingNCT07628127

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

Phase 3CompletedNCT05813795

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

16papers referencing Ecnoglutide

Emerging pharmacotherapies for obesity: A systematic review.

Pharmacol Rev2025

Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog.

Mol Metab2023

Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.

Nat Commun2024

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Diabetes Endocrinol2025

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.